Más opciones


Fecha de registro: 15 may 2022






. Feb 23, 2019 † . . The way you have it going sounds pretty good to me. Please let me know if you need help. ---------------------- Forwarded by Chris Germany/HOU/ECT on 02/21/2000 12:32 PM --------------------------- on 02/20/2000 03:08:05 PM To: " - *" cc: " - *Dalphon, Charles" , " - *Kinney, Douglas" Subject: Final Feb. CNG VOLUME Chris--You are correct. Attached is the updated invoice for February. Doug Kinney Ph: 703-561-6339 Fax: 703-561-7317 - Feb00_00.xlsThe release of soluble factor(s) by hypertrophied human myocardium is compatible with the induction of fibroblasts and the inhibition of myocyte growth and function. Human nonischemic hypertrophied hearts exhibited a 2- to 3-fold increase in the production of a 'fibroblast-inducer'(s) when compared to nonhypertrophied nonischemic hearts. The production of the factor(s) was significantly reduced by the simultaneous addition of polyclonal anti-endothelin-1 antiserum. Myocardial samples obtained from patients with ischemic cardiomyopathy exhibited similar levels of fibroblast-inducer(s) to those found in hypertrophied myocardium. In ischemic hearts, the production of the factor(s) was significantly reduced. It was increased in the presence of the angiotensin-converting enzyme inhibitor captopril. In addition, myocardial samples from patients with idiopathic dilated cardiomyopathy and with hypertrophic cardiomyopathy were found to produce significantly increased levels of the fibroblast-inducer when compared to nonischemic hearts. Similar changes were observed in hearts explanted from patients with end-stage heart failure (idiopathic and ischemic) compared to non-failing hearts.